Joanne Derdak

788 total citations
21 papers, 416 citations indexed

About

Joanne Derdak is a scholar working on Neurology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Joanne Derdak has authored 21 papers receiving a total of 416 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Neurology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Surgery. Recurrent topics in Joanne Derdak's work include Neurofibromatosis and Schwannoma Cases (11 papers), Neuroblastoma Research and Treatments (8 papers) and Sarcoma Diagnosis and Treatment (8 papers). Joanne Derdak is often cited by papers focused on Neurofibromatosis and Schwannoma Cases (11 papers), Neuroblastoma Research and Treatments (8 papers) and Sarcoma Diagnosis and Treatment (8 papers). Joanne Derdak collaborates with scholars based in United States, Italy and Canada. Joanne Derdak's co-authors include Patrick J. Mansky, Brigitte C. Widemann, Donna Bernstein, Seth M. Steinberg, Eva Dombi, Lori Wiener, Lauren Long, James C. Reynolds, Crystal L. Mackall and Crystal L. Mackall and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Clinical Cancer Research.

In The Last Decade

Joanne Derdak

21 papers receiving 408 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joanne Derdak United States 12 146 124 117 84 79 21 416
Matthias Schell France 12 183 1.3× 61 0.5× 95 0.8× 65 0.8× 149 1.9× 43 480
Cécile Thomas‐Teinturier France 12 99 0.7× 78 0.6× 214 1.8× 76 0.9× 100 1.3× 21 545
Jop C. Teepen Netherlands 11 42 0.3× 70 0.6× 168 1.4× 73 0.9× 74 0.9× 23 392
Rose B. McGee United States 9 76 0.5× 62 0.5× 138 1.2× 72 0.9× 71 0.9× 29 470
Cristina Veres France 11 62 0.4× 79 0.6× 171 1.5× 67 0.8× 34 0.4× 27 402
Chiraz El‐Fayech France 9 55 0.4× 82 0.7× 193 1.6× 50 0.6× 27 0.3× 14 374
Francesco Felicetti Italy 16 73 0.5× 61 0.5× 252 2.2× 133 1.6× 88 1.1× 36 636
Melissa M. Hudson United States 11 77 0.5× 61 0.5× 178 1.5× 94 1.1× 24 0.3× 20 429
Briana C. Patterson United States 13 156 1.1× 92 0.7× 385 3.3× 69 0.8× 78 1.0× 33 755
O. Oberlin France 12 102 0.7× 251 2.0× 74 0.6× 90 1.1× 88 1.1× 26 487

Countries citing papers authored by Joanne Derdak

Since Specialization
Citations

This map shows the geographic impact of Joanne Derdak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joanne Derdak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joanne Derdak more than expected).

Fields of papers citing papers by Joanne Derdak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joanne Derdak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joanne Derdak. The network helps show where Joanne Derdak may publish in the future.

Co-authorship network of co-authors of Joanne Derdak

This figure shows the co-authorship network connecting the top 25 collaborators of Joanne Derdak. A scholar is included among the top collaborators of Joanne Derdak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joanne Derdak. Joanne Derdak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gross, Andrea M., Lauren Baldwin, Ashley Cannon, et al.. (2025). Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib. JAMA Dermatology. 161(5). 533–533. 1 indexed citations
2.
Gross, Andrea M., Eva Dombi, Pamela L. Wolters, et al.. (2023). Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. Neuro-Oncology. 25(10). 1883–1894. 44 indexed citations
3.
Glod, John, Miki Kasai, Joanne Derdak, et al.. (2020). Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I–Related Plexiform Neurofibromas. Clinical Cancer Research. 26(23). 6112–6121. 21 indexed citations
4.
Jackson, Sadhana, Eva H. Baker, Andrea M. Gross, et al.. (2020). The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas. Neuro-Oncology Advances. 2(1). vdaa095–vdaa095. 23 indexed citations
5.
Coyne, Geraldine O’Sullivan, Andrea M. Gross, Eva Dombi, et al.. (2020). Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).. Journal of Clinical Oncology. 38(15_suppl). 3612–3612. 17 indexed citations
6.
Shalabi, Haneen, Constance M. Yuan, Alina Dulau‐Florea, et al.. (2020). Disease detection methodologies in relapsed B‐cell acute lymphoblastic leukemia: Opportunities for improvement. Pediatric Blood & Cancer. 67(4). e28149–e28149. 11 indexed citations
7.
Cohen, Julia W., Brigitte C. Widemann, Joanne Derdak, et al.. (2019). Cediranib phase‐II study in children with metastatic alveolar soft‐part sarcoma (ASPS). Pediatric Blood & Cancer. 66(12). e27987–e27987. 11 indexed citations
8.
Glod, John, Fernanda I. Arnaldez, Lori Wiener, et al.. (2019). A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor. Clinical Cancer Research. 25(21). 6302–6308. 17 indexed citations
9.
Glod, John, Julia W. Cohen, Brigitte C. Widemann, et al.. (2018). Cediranib phase II study in children with metastatic alveolar soft part sarcoma (ASPS).. Journal of Clinical Oncology. 36(15_suppl). 10540–10540. 2 indexed citations
10.
Jackson, Sadhana, Eva H. Baker, Andrea M. Gross, et al.. (2018). RARE-07. THE EFFECT OF SELUMETINIB ON SPINAL NEUROFIBROMAS IN PATIENTS WITH NF1. Neuro-Oncology. 20(suppl_6). vi237–vi237. 1 indexed citations
11.
12.
Glod, John, Fernanda I. Arnaldez, Lori Wiener, et al.. (2016). A phase II trial of vandetanib (ZD6474) in children and adults with wild-type gastrointestinal stromal tumors.. Journal of Clinical Oncology. 34(15_suppl). 11009–11009. 3 indexed citations
13.
Bradford, Diana, Patricia Whitcomb, Eva Dombi, et al.. (2016). Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).. Journal of Clinical Oncology. 34(15_suppl). TPS2596–TPS2596. 1 indexed citations
14.
Higham, Christine S., Sucharita Bhaumik, Eva Dombi, et al.. (2016). Atypical neurofibromas in neurofibromatosis 1 (NF1): Clinical, imaging and pathologic characteristics.. Journal of Clinical Oncology. 34(15_suppl). 11035–11035. 2 indexed citations
15.
Nella, Aikaterini A., Maya Lodish, Elizabeth Fox, et al.. (2014). Vandetanib Successfully Controls Medullary Thyroid Cancer-Related Cushing Syndrome in an Adolescent Patient. The Journal of Clinical Endocrinology & Metabolism. 99(9). 3055–3059. 34 indexed citations
16.
17.
Capitini, Christian M., Joanne Derdak, Marybeth S. Hughes, et al.. (2009). Unusual Sites of Extraskeletal Metastases of Ewing Sarcoma After Allogeneic Hematopoietic Stem Cell Transplantation. Journal of Pediatric Hematology/Oncology. 31(2). 142–144. 11 indexed citations
18.
Hoffman, Karen E., Joanne Derdak, Donna Bernstein, et al.. (2007). Metabolic syndrome traits in long‐term survivors of pediatric sarcoma. Pediatric Blood & Cancer. 50(2). 341–346. 48 indexed citations
19.
Wiener, Lori, Haven Battles, Donna Bernstein, et al.. (2006). Persistent psychological distress in long-term survivors of pediatric sarcoma: the experience at a single institution. Psycho-Oncology. 15(10). 898–910. 61 indexed citations
20.
Mansky, Patrick J., Andrew E. Arai, Pamela Stratton, et al.. (2006). Treatment late effects in long‐term survivors of pediatric sarcoma. Pediatric Blood & Cancer. 48(2). 192–199. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthias Schell Breakdown of academic impact, for papers by Cécile Thomas‐Teinturier Breakdown of academic impact, for papers by Jop C. Teepen Breakdown of academic impact, for papers by Rose B. McGee Breakdown of academic impact, for papers by Cristina Veres Breakdown of academic impact, for papers by Chiraz El‐Fayech Breakdown of academic impact, for papers by Francesco Felicetti Breakdown of academic impact, for papers by Melissa M. Hudson Breakdown of academic impact, for papers by Briana C. Patterson Breakdown of academic impact, for papers by O. Oberlin
Rankless by CCL
2026